Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031759 · ClinicalTrials.gov registry record · Phase 2
Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00031759 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 57 participants.
The verdict
NCT00031759, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells are removed in preventing cervical cancer in patients who have recurrent or persistent cervical neoplasia.
Interventions
- DRUG imiquimod
- PROCEDURE Ablative or excisional therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 1999-06 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031759
The ClinicalTrials.gov registry entry for NCT00031759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imiquimod is the first listed.
NCT00031759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031759 about?
NCT00031759 is a clinical study titled "Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia". RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of app...
What is the current status of trial NCT00031759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 1999-06. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00031759?
The interventions under investigation include: imiquimod (DRUG), Ablative or excisional therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00031759?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.